Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
KDMF
0
VMF
0
FDF
0
Australia
0
South Africa
0
Listed Dossiers
0
EDQM
0
USP
0
JP
0
Others
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 1354744-91-4
2. Nktr-118 Oxalate
3. Naloxegol (oxalate)
4. Naloxegol Oxalate [usan]
5. Az13337019 Oxalate
6. Az-13337019 Oxalate
7. 65i14tnm33
8. Moventig
9. (4r,4as,7s,7ar,12bs)-7-[2-[2-[2-[2-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]-3-prop-2-enyl-1,2,4,5,6,7,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-4a,9-diol;oxalic Acid
10. Naloxegol Oxalate (usan)
11. Unii-65i14tnm33
12. Movantik (tn)
13. Moventig (tn)
14. Nktr-118-oxalate
15. Naloxegol Oxalate [mi]
16. Naloxegol Oxalate(nktr-118)
17. Chembl2219416
18. Schembl20839999
19. Hy-a0118a
20. Dtxsid50159395
21. Naloxegol Oxalate [who-dd]
22. Akos030526444
23. Cs-5349
24. Naloxegol Oxalate [orange Book]
25. Nktr-118;az-13337019 Oxalate
26. Ac-36031
27. Movantik Component Naloxegol Oxalate
28. Az 13337019
29. Naloxegol Oxalate Component Of Movantik
30. D10375
31. Q27263878
32. 4,5.alpha.-epoxy-6.alpha.-((3,6,7,12,15,18,21-heptaoxadocosyl)oxy)-17-(prop-2-enyl)morphinan-3,14-diol Hydrogen Ethanedioate
33. 4,5alpha-epoxy-6alpha-((3,6,7,12,15,18,21-heptaoxadocosyl)oxy)-17-(prop-2-enyl)morphinan-3,14-diol Hydrogen Ethanedioate
34. Morphinan-3,14-diol, 4,5-epoxy-6-(3,6,9,12,15,18,21-heptaoxadocos-1-yloxy)-17-(2-propen-1-yl)-, (5.alpha.,6.alpha.)-, Ethanedioate (1:1)
35. Morphinan-3,14-diol, 4,5-epoxy-6-(3,6,9,12,15,18,21-heptaoxadocos-1-yloxy)-17-(2-propen-1-yl)-, (5alpha,6alpha)-, Ethanedioate (1:1)
Molecular Weight | 741.8 g/mol |
---|---|
Molecular Formula | C36H55NO15 |
Hydrogen Bond Donor Count | 4 |
Hydrogen Bond Acceptor Count | 16 |
Rotatable Bond Count | 25 |
Exact Mass | 741.35717005 g/mol |
Monoisotopic Mass | 741.35717005 g/mol |
Topological Polar Surface Area | 201 Ų |
Heavy Atom Count | 52 |
Formal Charge | 0 |
Complexity | 971 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 5 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
Treatment of opioid-induced constipation (OIC) in adult patients who have had an inadequate response to laxative(s).
A06AH03
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
A Naloxegol manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Naloxegol, including repackagers and relabelers. The FDA regulates Naloxegol manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Naloxegol API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Naloxegol manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Naloxegol supplier is an individual or a company that provides Naloxegol active pharmaceutical ingredient (API) or Naloxegol finished formulations upon request. The Naloxegol suppliers may include Naloxegol API manufacturers, exporters, distributors and traders.
click here to find a list of Naloxegol suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Naloxegol DMF (Drug Master File) is a document detailing the whole manufacturing process of Naloxegol active pharmaceutical ingredient (API) in detail. Different forms of Naloxegol DMFs exist exist since differing nations have different regulations, such as Naloxegol USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Naloxegol DMF submitted to regulatory agencies in the US is known as a USDMF. Naloxegol USDMF includes data on Naloxegol's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Naloxegol USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Naloxegol suppliers with USDMF on PharmaCompass.
A Naloxegol written confirmation (Naloxegol WC) is an official document issued by a regulatory agency to a Naloxegol manufacturer, verifying that the manufacturing facility of a Naloxegol active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Naloxegol APIs or Naloxegol finished pharmaceutical products to another nation, regulatory agencies frequently require a Naloxegol WC (written confirmation) as part of the regulatory process.
click here to find a list of Naloxegol suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Naloxegol as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Naloxegol API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Naloxegol as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Naloxegol and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Naloxegol NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Naloxegol suppliers with NDC on PharmaCompass.
Naloxegol Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Naloxegol GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Naloxegol GMP manufacturer or Naloxegol GMP API supplier for your needs.
A Naloxegol CoA (Certificate of Analysis) is a formal document that attests to Naloxegol's compliance with Naloxegol specifications and serves as a tool for batch-level quality control.
Naloxegol CoA mostly includes findings from lab analyses of a specific batch. For each Naloxegol CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Naloxegol may be tested according to a variety of international standards, such as European Pharmacopoeia (Naloxegol EP), Naloxegol JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Naloxegol USP).
LOOKING FOR A SUPPLIER?